Remember E5

Xoma Corp. and partner Pfizer Inc. finally threw in the towel in their efforts to make XOMA's E5 monoclonal antibody work in sepsis, providing a reminder of earlier spectacular letdowns against the bacterial infection.

Pfizer (New York, N.Y.) and XOMA (Berkeley, Calif.) halted their third Phase III trial with E5

Read the full 496 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE